'Trump effect' raises hopes for cannabis rally as investors bet on federal reforms, softer marijuana stance

Cannabis stocks are experiencing renewed investor optimism, driven by potential federal regulatory shifts, including signals from Donald Trump regarding Medicare coverage for CBD and the reclassification of marijuana from Schedule I to Schedule III. Such changes would significantly ease sales, banking access, and research, while removing burdensome IRS 280E tax restrictions, potentially marking a major inflection point for the sector despite recent mixed earnings and a 10% YTD decline in cannabis ETFs. Although some Republican lawmakers advocate for stricter hemp regulations due to safety concerns, industry leaders view clear federal standards as crucial for legitimizing the market, attracting institutional capital, and unlocking substantial growth towards a projected $160 billion global market for cannabis-derived products by 2032.

Analysis

Cannabis stocks show renewed investor optimism despite a ~10% YTD sector decline, driven by potential federal regulatory shifts. President Trump's signals on CBD and marijuana reclassification (Schedule I to III), plus congressional hemp regulation efforts, are seen as a critical inflection point for a market projected to reach $160 billion globally by 2032.

Company performance is mixed; Verano Holdings reported $203 million revenue but a $44 million net loss, contrasting with Tilray Brands' 22% stock surge post-Q1 results. Federal rescheduling would significantly ease sales, banking, and remove IRS 280E tax restrictions, crucial for legitimizing the industry and attracting institutional capital.

The industry seeks clear federal standards for hemp-derived products, yet faces Republican pushback for stricter regulations or bans due to safety concerns and market oversaturation. While regulation is vital for sustainable growth, a complete ban could severely impact the $1.6 billion hemp economy.

Investor optimism is partly fueled by perceived political influence, notably through Trump's chief of staff and her ties to Trulieve. Despite policy uncertainty, the perception of regulatory change has already spurred significant stock movements, with the market's future largely hinging on regulatory clarity from the next administration.

Key Decisions for Investors

• Investors should closely monitor political developments, particularly regarding federal marijuana rescheduling and Farm Bill updates, as regulatory clarity will be the primary catalyst for sector performance and institutional capital inflow.
• Given mixed company fundamentals and high sector speculation, investors should conduct thorough due diligence on individual cannabis companies, distinguishing between those with strong balance sheets and growth prospects versus those facing operational challenges.
• Acknowledge the significant regulatory uncertainty and political headwinds, including potential Republican-led restrictions on hemp-derived products, and consider hedging strategies or maintaining a cautious stance until clearer federal guidance emerges.